⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 15, 2025Open Access

Figure S11 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer

Tianyu Qu Lei Song Jiali Xu Xiyi Lu Dandan Yin Jiali Dai Chen Zhang Renhua Guo Erbao Zhang

View Full Paper

Ask AI

Bookmark

Share

Key Points

Enhanced glutamine metabolism promotes EGFR inhibitor resistance in non-small cell lung cancer.
The c-Myc/METTL3/MYLK-AS1/ILF3/GLUD1 axis is pivotal for metabolic adaptation in cancer cells.
Analysis highlights the role of MYLK-AS1 in mitochondrial glutamine metabolism and drug resistance mechanisms.
Understanding this regulatory axis may guide future therapeutic strategies for overcoming resistance in lung cancer.

Implication

Observational analysis reveals enhanced glutamine metabolism in non-small cell lung cancer, suggesting MYLK-AS1 contributes to drug resistance.

Abstract

The c-Myc/METTL3/MYLK-AS1/ILF3/GLUD1 regulatory axis enhances mitochondrial glutamine metabolism.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Qu et al. (2025) studied this question.

synapsesocial.com/papers/68af50a1ad7bf08b1ead8998 https://doi.org/10.1158/0008-5472.29919063

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
2Figure S9 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
3Figure S10 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
4Figure S6 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025
5Figure S4 from MYLK-AS1 Enhances Glutamine Metabolism to Promote EGFR Inhibitor Resistance in Non–Small Cell Lung Cancer2025